Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TRDA
stocks logo

TRDA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.49M
-77.29%
-0.945
-3250%
5.14M
-75%
-0.960
+128.57%
487.50K
-75%
-1.083
+4.09%
Estimates Revision
The market is revising Downward the revenue expectations for Entrada Therapeutics, Inc. (TRDA) for FY2025, with the revenue forecasts being adjusted by -4.25% over the past three months. During the same period, the stock price has changed by 92.06%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.2%
In Past 3 Month
Stock Price
Go Up
up Image
+92.06%
In Past 3 Month
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.160
sliders
Low
13.00
Averages
16.50
High
20.00
Current: 10.160
sliders
Low
13.00
Averages
16.50
High
20.00
Roth Capital
Buy
downgrade
$17 -> $13
2025-11-06
Reason
Roth Capital
Price Target
$17 -> $13
2025-11-06
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $13 from $17 and keeps a Buy rating on the shares. Management guided that preliminary proof-of-concept efficacy results from the ongoing global Phase 1/2 study of ENTR-601-44 and ENTR-601-45 are expected in 2Q26 and mid-2026, respectively, the analyst tells investors in a research note. While the firm remains enthusiastic about the company's pipeline programs, it lowered its price target on the shares to reflect the broader market sentiment and advances made by competing agents.
Goldman Sachs
Paul Choi
initiated
2025-09-17
Reason
Goldman Sachs
Paul Choi
Price Target
2025-09-17
initiated
Reason
Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics with an Early-Stage Biotech designation, saying the company's Endosomal Escape Vehicle platform is differentiated from other delivery peptide approaches. It sees "best-in-class potential."
Roth Capital
Buy
downgrade
$21 -> $17
2025-08-07
Reason
Roth Capital
Price Target
$21 -> $17
2025-08-07
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $17 from $21 and keeps a Buy rating on the shares after meeting with its management to discuss the company's DMD clinical programs, particularly, ENTR-601-44 and ENTR-601-45. The company's robust cash position and multiple clinical data readouts anticipated in 2026 drive the firm's optimism, though Roth is also acknowledging the broader negative sentiment enshrouding the company's stock, partly fueled by a lack of value driving data catalyst events in 2025, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$23 -> $21
2025-05-12
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$23 -> $21
2025-05-12
downgrade
Buy
Reason
Roth Capital
Buy
downgrade
$23 -> $21
2025-05-11
Reason
Roth Capital
Price Target
$23 -> $21
2025-05-11
downgrade
Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-03-31
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-03-31
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Entrada Therapeutics Inc (TRDA.O) is -2.50, compared to its 5-year average forward P/E of -15.93. For a more detailed relative valuation and DCF analysis to assess Entrada Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.93
Current PE
-2.50
Overvalued PE
37.05
Undervalued PE
-68.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.06
Undervalued EV/EBITDA
-6.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.91
Current PS
0.00
Overvalued PS
12.78
Undervalued PS
1.05
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 374.09% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 374.09% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

TRDA News & Events

Events Timeline

(ET)
2025-11-06
07:11:59
Entrada Therapeutics Announces Q3 Earnings Per Share of $1.06, Exceeding Consensus Estimate of 96 Cents
select
2025-08-06 (ET)
2025-08-06
07:03:14
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
select
2025-06-03 (ET)
2025-06-03
07:09:25
Entrada Therapeutics appoints Radhakrishnan to board of directors
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
06:20 AMGlobenewswire
Entrada Therapeutics Grants 40,650 RSUs and Options to New Employees
  • Employee Incentive Program: Entrada Therapeutics granted 40,650 restricted stock units and options for 38,850 shares to five newly hired non-executive employees under its 2025 Inducement Equity Plan, aimed at attracting talent and enhancing team stability.
  • Option Exercise Price: The options have an exercise price of $9.91 per share, matching the closing price of the company's common stock on December 1, 2025, ensuring that employee interests are closely aligned with the company's stock performance.
  • Vesting Schedule: Each employee's options will vest one-fourth on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in thirty-six equal monthly installments, which helps to improve long-term employee retention.
  • Strategic Company Development: By implementing the Inducement Equity Plan, Entrada not only attracts key talent but also enhances its competitiveness in the biopharmaceutical industry, facilitating progress in its therapeutic programs targeting neuromuscular and ocular diseases.
[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?

  • 5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.

  • Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.

  • Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.

  • Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.

[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note

  • 5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.

  • Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.

  • Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.

  • Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Entrada Therapeutics Inc (TRDA) stock price today?

The current price of TRDA is 10.16 USD — it has increased 0.89 % in the last trading day.

arrow icon

What is Entrada Therapeutics Inc (TRDA)'s business?

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

arrow icon

What is the price predicton of TRDA Stock?

Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Entrada Therapeutics Inc (TRDA)'s revenue for the last quarter?

Entrada Therapeutics Inc revenue for the last quarter amounts to 1.61M USD, decreased -91.75 % YoY.

arrow icon

What is Entrada Therapeutics Inc (TRDA)'s earnings per share (EPS) for the last quarter?

Entrada Therapeutics Inc. EPS for the last quarter amounts to -1.06 USD, increased 202.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Entrada Therapeutics Inc (TRDA)'s fundamentals?

The market is revising Downward the revenue expectations for Entrada Therapeutics, Inc. (TRDA) for FY2025, with the revenue forecasts being adjusted by -4.25% over the past three months. During the same period, the stock price has changed by 92.06%.
arrow icon

How many employees does Entrada Therapeutics Inc (TRDA). have?

Entrada Therapeutics Inc (TRDA) has 183 emplpoyees as of December 05 2025.

arrow icon

What is Entrada Therapeutics Inc (TRDA) market cap?

Today TRDA has the market capitalization of 388.69M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free